Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 2 at 2:00 PM EDT

Register Free →

Vehicle Recompete: Bpa 75H71123A00121

Active
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The contract BPA vehicle 75H71123A00121, managed by the Indian Health Service under the Department of Health and Human Services, is focused on diabetic foot supplies and services. It has an indefinite delivery vehicle (IDV) ceiling of $245,000 with no active task orders currently underway, though it includes a past task order valued at $50,000 awarded to Mid Star Lab Inc. The ordering period for this contract extends until September 14, 2027. The contract is identified as a recompete with medium confidence, indicating that it is likely to be renewed or competed again in the future. This contract covers procurement under NAICS code 316210 and serves the Indian Health Service's requirements related to diabetic foot care products and services. While specific details on the solicitation and place of performance are not provided, the contract remains an important procurement vehicle supporting healthcare-related supply needs within the Department of Health and Human Services framework. The contract is currently in a pre-forecast stage, with the recompete process anticipated to begin around March 2026.

General Info

Indian Health Service diabetic foot supplies contract, $245K ceiling, no current orders, expires 2027.

Agency

Department Of Health And Human Services → Indian Health ServiceView Agency

NAICS

316210 - Footwear ManufacturingView NAICS

Place of Performance

Not specified

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

pre-forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → Indian Health Service
ContactsNo contacts available
OfficeN/A
Organization / Agency
Department Of Health And Human Services → Indian Health Service
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Bpa vehicle 75H71123A00121 ordering period ends 2027-09-14T00:00:00.000Z. 0 active task orders valued at $0.
Diabetic foot supplies and services haskell ihs IDV Ceiling: $245,000 Contracting Office: Indian Health Service Agencies: Department of Health and Human Services Classification: recompete-likely (Confidence: medium - 50/100)
Top task orders by value: - DIABETIC FOOT SUPPLIES AND SERVICES HASKELL IHS ($50,000) - MID STAR LAB INC

Similar Contracts

Same NAICS industry code

NAICS: 316210
Federal
Safety Boots Follow-On for Fort Riley, KS
Solicitation # FTRILEY26Q1BL7
The Department of Defense, through the W6QM Micc-Ft Riley, has issued a sources-sought notice for the follow-on procurement of safety and muck boots for Department of Public Works (DPW) workers at Fort Riley, Kansas. The requirement involves supplying varying quantities of footwear that must meet strict technical safety standards, including ASTM F2413-18 for impact, compression, and electrical hazard protection, as well as ASTM F2913 for slip resistance. Boots must be 100% waterproof, available in a wide range of sizes for both men and women, and offered in multiple widths, including custom options upon request. To ensure proper ergonomic fit for all employees, the contract mandates that the vendor be located within a 60-mile radius of Fort Riley to facilitate in-person fittings. The procurement is structured with a not-to-exceed price cap of $160 per pair and is expected to follow a Lowest Price Technically Acceptable (LPTA) award basis. Key performance obligations include a minimum 12-month warranty covering material and workmanship defects and a no-cost fit guarantee that requires the contractor to process exchanges within 15 business days. The contractor is responsible for all shipping and handling costs associated with the return of defective items and the delivery of replacements. Administrative requirements include submitting invoices through the Wide Area Workflow (WAWF) system and providing a DD Form 250 with each submission. The response deadline for this market research notice is August 28, 2026.
W6QM Micc-Ft Riley

POSTED

7 days ago

DEADLINE

in 4 days
View Details

More opportunities from Department Of Health And Human Services → Indian Health Service

Same awarding agency

NAICS: 541715
SBIR / STTR
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
Solicitation # PA-27-102
This solicitation supports Small Business Technology Transfer (STTR) grants through the National Institutes of Health to fund research and development projects that advance innovative technologies with potential for commercialization, requiring a formal collaboration between a U.S.-owned small business and a nonprofit research institution. The award is made solely to the small business, regardless of where the principal investigator is employed, and projects must align with the missions of NIH, CDC, or FDA components. Funding is available for Phase I, Phase II, Direct to Phase II, and Fast-Track applications, with Fast-Track allowing combined Phase I and II review to streamline the process. Direct to Phase II is an option for businesses that have already demonstrated technical merit without prior Phase I funding, provided the application is submitted as a new proposal, not a renewal. Only one Phase II award is permitted per Phase I project, and Phase IIB Strategic Breakthrough applications must go through a separate solicitation. Applications must focus on feasibility or R&D that supports public health goals and are subject to restrictions on clinical trials, which are not permitted under this NOFO if exclusively aligned with specific NIH institutes including NIAID, NIAMS, NIDCR, NIDDK, NIMHD, NCATS, and ORIP. The funding opportunity is part of the broader SBIR/STTR mandate, which requires NIH to set aside 0.45% of its extramural budget for STTR, ensuring support for small businesses with fewer than 500 employees. Applicants are encouraged to consult with program staff prior to submission to ensure alignment with funding priorities and to use the Assignment Request Form to suggest an appropriate awarding component, though such identification is not mandatory. The solicitation closes on August 5, 2026, and information on program details, priorities, and frequently asked questions is available through the NIH Seed Fund portal and related government strategies including the Make Our Children Healthy Again initiative.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

3 months ago

DEADLINE

in 7 months
View Details
NAICS: 541715
SBIR / STTR
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
Solicitation # PA-27-100
This funding opportunity supports U.S. small businesses in advancing early-stage research and development toward commercialization through the SBIR program, administered by the National Institutes of Health, Centers for Disease Control and Prevention, and Food and Drug Administration. Eligible small businesses must be U.S.-owned and operated with fewer than 500 employees and are expected to lead the majority of the technical effort, with the principal investigator primarily employed by the business. The program offers Phase I grants to establish technical feasibility, Phase II grants to advance development toward market readiness, and two special pathways: Direct to Phase II for projects with prior proof of concept but no prior Phase I award, and Fast-Track for combined Phase I and Phase II submissions reviewed concurrently to accelerate progress. All awards are granted to the small business, and commercialization must be pursued using non-SBIR funds after Phase II. The scientific scope must align with the missions of participating NIH, CDC, or FDA components, focusing on health improvement and public health innovation, with applicants encouraged to consult specific institute priorities and the White House’s Make Our Children Healthy Again Strategy. While clinical trials are permitted, they are explicitly excluded if the application aligns solely with certain NIH institutes or all FDA centers, making alignment critical for responsiveness. Applications must be submitted through the designated portal by the deadline, and while applicants are not required to specify an awarding component during submission, consultation with program staff beforehand is strongly advised to ensure proper alignment. The solicitation operates under a complete small business set-aside mandate and is open to new applications only, with no renewals accepted for Direct to Phase II submissions.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

3 months ago

DEADLINE

in 7 months
View Details
NAICS: 541715
SBIR / STTR
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
Solicitation # PAR-27-098
The Commercialization Readiness Pilot (CRP) program, issued under PAR-27-098, provides late-stage research and development funding and technical assistance to U.S. small business concerns that have previously received an NIH SBIR or STTR Phase II award or a Phase IIB Strategic Breakthrough award. This initiative is designed to bridge the gap between Phase II completion and full commercialization by supporting activities that require significant outsourcing, such as regulatory strategy, intellectual property development, manufacturing optimization, pre-clinical product development, and clinical trials—though not all NIH institutes accept clinical trial proposals. The program permits substantial outsourcing to contract research organizations but requires the small business to maintain active oversight and management of all scientific, financial, and administrative aspects of the work, with justified budget allocations reflecting this role. CRP funding cannot cover FDA filing fees or include separate Technical and Business Assistance (TABA) funds. Eligible applicants must be small business concerns under 500 employees meeting SBA size standards, and proposals must align with the mission of participating NIH components. The solicitation explicitly excludes applications that propose clinical trials solely aligned with certain NIH institutes, including NHLBI, NIAID, NIDDK, and others listed, which do not accept such trials under this program. Applications are limited to Type 1 new submissions, and prior Phase II funding is mandatory for eligibility. Applicants are strongly encouraged to consult with NIH program staff before submitting to ensure alignment with the most appropriate funding mechanism, as the Phase IIB Strategic Breakthrough program (PA-27-101) may be better suited for some projects with matching fund requirements. The solicitation is active through August 5, 2026, under a total small business set-aside, and further details are available through the NIH SBIR/STTR portal.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

3 months ago

DEADLINE

in 7 months
View Details